Scholar Rock Raises $36M in Series B Financing

Scholar_Rock_logoScholar Rock, a Cambridge, MA-based biotechnology company focused on discovering and developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment, raised $36m in Series B financing.

The round was led by Fidelity Management and Research Company with participation from new investor Cormorant Asset Management and existing investors Polaris Partners, Timothy Springer, ARCH Venture Partners, EcoR1 Capital and The Kraft Group.

The company intends to use the funds to continue to advance its pipeline of therapeutic candidates.

Founded by Professors Timothy Springer, PhD, and Leonard Zon, MD, of Boston Children’s Hospital and Harvard Medical School, and led by Nagesh Mahanthappa, PhD, President and Chief Executive Officer, Scholar Rock has developed a supracellular activation platform and drug discovery programs that target specific growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology and autoimmune diseases.



Join the discussion